Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines

Expert Opinion on Drug Delivery

Volumn 7, Issue 9, 2010, Pages 1109-1125

  Vankerckhoven, Vanessa ^a   Van Damme, Pierre ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Device; Immune response; Influenza; Intradermal vaccine; Review; Safety

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; B LYMPHOCYTE ACTIVATION; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; DRUG SAFETY; EPIDEMIC; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INCIDENCE; INFLUENZA; INFLUENZA VIRUS A H1N1; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MACROPHAGE; MICROINJECTION; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; VACCINATION REACTION;

ANTIGENS, VIRAL; CLINICAL TRIALS AS TOPIC; EUROPE; GUIDELINES AS TOPIC; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; MASS VACCINATION;

EID: 77955866098     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2010.507668     Document Type: Review

References (81)

1. World Health Organization. Influenza fact sheet N0211. Available from: www who int/mediacentre/factsheets/fs211 [Last accessed July 5, 2010]
2. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005;353(24):2559-2567
3. Chiu SS, Lau YL, Chan KH, et al. Influenza-related hospitalizations among children in Hong Kong. N Engl J Med 2002;347(26):2097-2103
4. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342(4):232-239
5. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342(4):225-231
6. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 2004;113(3 Pt 1):585-593
7. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med 2006;355(1):31-40
8. Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2006;55:1-42
9. The European Agency for the Evaluation of Medicinal Products (EMA). Committee for proprietary medicinal products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines. CPMP/BWP/214/96 1997
10. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine 2007;25(32):5945-5957
11. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2009;58:1-52
12. World Health Organization. Prevention and control of influenza pandemics and annual epidemics. 56th World Assembly 2003;WHA56.19
13. Council of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination. Available from: http://eur-lexeuropa eu/LexUriServ/LexUriServ do? uri = OJ: L: 2009:348:00710072:EN:PDF 2009
14. Blank PR, Schwenkglenks M, Szucs TD. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 2008;8:272
15. de Lataillade C, Auvergne S, Delannoy I. 2005 and 2006 seasonal influenza vaccination coverage rates in 10 countries in Africa, Asia Pacific, Europe, Latin America and the Middle East. J Public Health Policy 2009;30(1):83-101
16. Tuft L. Active immunization against typhoid fever with particular reference to an intradermal method. J Lab Clin Med 1931;16:552
17. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008;7(8):1201-1214
18. Valladeau J, Saeland S. Cutaneous dendritic cells. Semin Immunol 2005;17(4):273-283
19. Le Borgne M, Etchart N, Goubier A, et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/ CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 2006;24(2):191-201
20. Allan RS, Waithman J, Bedoui S, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006;25(1):153-162
21. Reddy ST, van d V, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007;25(10):1159-1164
22. Briggs DJ, Banzhoff A, Nicolay U, et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000;78(5):693-698
23. Bryan JP, Sjogren MH, Perine PL, Legters LJ. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis 1992;14(3):697-707
24. Redfield RR, Innis BL, Scott RM, et al. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 1985;254(22):3203-3206
25. Payler DK, Skirrow MB. Letter: intradermal influenza vaccination. Br Med J 1974;2(5921):727
26. Centers for Disease Control and Prevention. State-specific influenza vaccination coverage among adults aged > = 18 years- United States, 2003- 2004 and 2005-2006 influenza seasons. MMWR Morb Mortal Wkly Rep 2007, 56(37) 953-959
27. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351(22):2286-2294
28. Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351(22):2295-2301
29. World Health Organization. Current WHO phase of pandemic alert. Available from: who int/csr/ disease/avian-influenza/phase/en/ [Last accessed June 23, 2010]
30. Valdespino-Gomez JL, Garcia-Garcia L, de Leon-Rosales SP. Vaccines against influenza A (H1N1) pandemic. Arch Med Res 2009;40(8):693-704
31. World Health Organization. Pandemic influenza vaccines: current status. Pandemic (H1N1) 2009 briefing note 11. Available from: www who int/csr/disease/swineflu/notes/ pandemic-influenza-vaccines-20090924/en [Last accessed June 23, 2010]
32. Partridge J, Kieny MP, the World Health Organization H1N1 influenza vaccine Taske Force. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine 2010;28(30):4709-4712
33. Nava GM, ttene-Ramos MS, Ang JK, Escorcia M. Origins of the new influenza A(H1N1) virus: time to take action. Euro Surveill 2009;14(22)
34. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24(8):1159-1169
35. Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2004;53:1-40
36. Gomez CR, Nomellini V, Faunce DE, Kovacs EJ. Innate immunity and aging. Exp Gerontol 2008;43(8):718-728
37. Shurin MR, Shurin GV, Chatta GS. Aging and the dendritic cell system: implications for cancer. Crit Rev Oncol Hematol 2007;64(2):90-105
38. Paccalin M, Weinberger B, Nicolas J-F, et al. The intradermal vaccination route- an attractive opportunity for influenza vaccination in elderly. Eur Geriatr Med 2010;1:82-87
39. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35(1):69-75
40. Monto AS, Ohmit SE. Seasonal influenza vaccines: evolutions and future trends. Expert Rev Vaccines 2009;8(4):383-389
41. Van Gelder DW, Greenspan FS, Dufresne NE. Influenza vaccination; comparison of intracutaneous and subcutaneous methods. US Nav Med Bull 1947;47(1):197-206
42. Weller TH, Cheever FS, Enders JF. Immunologic reactions following the intradermal inoculation of influenza A and B vaccine. Proc Soc Exp Biol Med 1948;67(1):96-101
43. Boger WP, Liu OC. Subcutaneous and intradermal vaccination with Asian influenza vaccine. J Am Med Assoc 1957;165(13):1687-1689
44. Phillips CA, Forsyth BR, Christmas WA, et al. Purified influenza vaccine: clinical and serologic responses to varying doses and different routes of immunization. J Infect Dis 1970;122(1):26-32
45. Marks MI, Eller JJ. Intradermal influenza immunization. Experience with Hong Kong vaccine. Am Rev Respir Dis 1971;103(4):579-581
46. McCarroll JR, Kilbourne ED. Immunization with Asian-strain influenza vaccine: equivalence of the subcutaneous and intradermal routes. N Engl J Med 1958;259(13):618-621
47. Foy HM, Sealey L, Cooney MK, Bor E. Efficacy of intradermally administered A2 Hong Kong vaccine. JAMA 1970;213(1):130
48. McElroy JT, Szwed JJ. Response to intradermal vaccination with A2, Hong Kong variant, influenza vaccine. N Engl J Med 1969;6:1076
49. Brown H, Kasel JA, Freeman DM, et al. The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J Infect Dis 1977;136(Suppl):S466-71
50. Halperin W, Weiss WI, Altman R, et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am J Public Health 1979;69(12):1247-1251
51. Brooks JH, Criep LH, Ruben FL. Intradermal administration of bivalent and monovalent influenza vaccines. Ann Allergy 1977;39(2):110-112
52. World Health Organization. Influenza vaccines. WHO position paper. Wkly Epidemiol Rec 2005;80:277-287
53. Auewarakul P, Kositanont U, Sornsathapornkul P, et al. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007;25(4):659-663
54. Belshe RB, Newman FK, Wilkins K, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007;25(37-38):6755-6763
55. Kunzi V, Klap JM, Seiberling MK, et al. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 2009;27(27):3561-3567
56. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000;18(26):3040-3049
57. Palache AM, Beyer WE, Luchters G, et al. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine 1993;11(9):892-908
58. Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J Infect Dis 1979;140(2):234-238
59. Chuaychoo B, Wongsurakiat P, Nana A, et al. The immunogenicity of intradermal influenza vaccination in COPD patients. Vaccine 2010;28(24):4045- 4051
60. Khanlou H, Sanchez S, Babaie M, et al. The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients. Arch Intern Med 2006;166(13):1417
61. Gelinck LB, van den Bemt BJ, Marijt WA, et al. Intradermal influenza vaccination in immunocompromised patients is immunogenic and feasible. Vaccine 2009;27(18):2469-2474
62. Manuel O, Humar A, Chen MH, et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant 2007;7(11):2567-2572
63. Jo YM, Song JY, Hwang IS, et al. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol 2009;81(4):722-727
64. Klein M, Huang N. The response of infants and children to Asian influenza vaccine administered by intradermal and subcutaneous routes. J Pediatr 1961;58:312-314
65. Chiu SS, Peiris JS, Chan KH, et al. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007;119(6):1076-1082
66. Sugimura T, Ito Y, Tananari Y, et al. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine 2008;26(22):2700-2705
67. Chiu SS, Chan KH, Tu W, et al. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. Vaccine 2009;27(35):4834-4839
68. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359(15):1555-1564
69. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008;26(26):3197-3208
70. Mikszta JA, Laurent PE. Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook. Expert Rev Vaccines 2008;7(9):1329-1339
71. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009;27(3):454-459
72. Leroux-Roels I, Vets E, Freese R, et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine 2008;26(51):6614-6619
73. Beran J, Ambrozaitis A, Laiskonis A, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009;7:13
74. Holland D, Booy R, De LF, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008;198(5):650-658
75. Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009;27(52):7304-7312
76. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007;56:1-54
77. Mathei C, Van Damme P, Meheus A. Hepatitis B vaccine administration: comparison between jet-gun and syringe and needle. Vaccine 1997;15(4):402-404
78. Laurent PE, Bonnet S, Alchas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007;25(52):8833-8842
79. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004;350(9):896-903
80. Macroepidemiology of Influenza Vaccination (MIV) Study Group. The macro-epidemiology of influenza vaccination in 56 countries, 1997- 2003. Vaccine 2005, 23(44): 5133-5143
81. Chen D, Burger M, Chu Q, et al. Epidermal powder immunization: cellular and molecular mechanisms for enhancing vaccine immunogenicity. Virus Res 2004;103(1-2):147-153